Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea

Completed · Phase 3

Conditions studied: Erythema, Rosacea

In brief

This study will evaluate the safety and efficacy of AGN-199201 once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.

Key facts

Study ID

NCT02131636

Run by

Allergan

People needed

440

Starts

2014-05-01

Expected to finish

2014-12-01

Last updated by the study team

2019-11-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Moderate to severe persistent facial erythema associated with rosacea.

You may not qualify if…

• Greater than 3 inflammatory lesions on the face
• Current treatment with monoamine oxidase (MAO) inhibitors
• Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, scleroderma or Sjogren's syndrome.

Where it is running

• Study site — Lynchburg, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.